Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$32 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
8.5
Industry P/E
74.17
EV/EBITDA
0.2
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$--
EPS
$-1.6
Face value
--
Shares outstanding
16,085,800
CFO
$-55.46 Mln
EBITDA
$-63.68 Mln
Net Profit
$-212.05 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aethlon Medical (AEMD)
| -73.2 | -37.1 | -44.6 | -58.2 | -72.6 | -55.6 | -56.9 |
|
BSE Sensex
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Aethlon Medical (AEMD)
| -60.4 | -20.5 | -84.9 | -24.7 | 156.5 | -96.1 | 46.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aethlon Medical (AEMD)
|
1.8 | 32.5 | 0.0 | -9.6 | -- | -0.4 | -- | 8.5 |
| 13.3 | 9,212.9 | 6,685.2 | 715.6 | 16.4 | 12.3 | 12.9 | 1.5 | |
| 250.1 | 6,705.7 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 1.0 | |
| 227.9 | 6,283.8 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 0.9 | |
| 39.3 | 6,018.9 | 3,446.1 | 79.6 | 7.5 | 4.4 | 77.9 | 3.3 | |
| 59.5 | 8,231.0 | 2,510.8 | 185.6 | 8.8 | 4.5 | 45 | 2.0 | |
| 70.5 | 8,892.9 | 12,669.0 | 407.0 | 5.4 | 11.8 | 22.2 | 2.7 | |
| 159.9 | 9,055.1 | 1,973.6 | -494.5 | -11.4 | -41 | -- | 9.8 | |
| 255.1 | 9,809.7 | 1,240.1 | 42.2 | 4.1 | 3.6 | 239 | 8.1 | |
| 129.9 | 7,416.2 | 645.7 | -25.4 | 6.8 | -1.3 | -- | 3.7 |
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device for cancer and... life-threatening viral infections and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California. Address: 11555 Sorrento Valley Road, San Diego, CA, United States, 92121 Read more
Chief Operating Officer
Mr. Guy F. Cipriani BS (Eng.), MBA
Chief Operating Officer
Mr. Guy F. Cipriani BS (Eng.), MBA
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Aethlon Medical Inc (AEMD) stood at $ 8 Mln as on 31-Dec-24
The share price of Aethlon Medical Inc (AEMD) is $1.84 (NASDAQ) as of 13-Jun-2025 10:30 EDT. Aethlon Medical Inc (AEMD) has given a return of -72.61% in the last 3 years.
Aethlon Medical Inc (AEMD) has a market capitalisation of $ 32 Mln as on 12-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Aethlon Medical Inc (AEMD) is 8.54 times as on 12-Jun-2025, a 147% premium to its peers’ median range of 3.46 times.
Since, TTM earnings of Aethlon Medical Inc (AEMD) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aethlon Medical Inc (AEMD) and enter the required number of quantities and click on buy to purchase the shares of Aethlon Medical Inc (AEMD).
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device for cancer and life-threatening viral infections and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California. Address: 11555 Sorrento Valley Road, San Diego, CA, United States, 92121
The CEO & director of Mr. Guy F. Cipriani BS (Eng.), MBA. is Aethlon Medical Inc (AEMD), and CFO & Sr. VP is Mr. Guy F. Cipriani BS (Eng.), MBA.
There is no promoter pledging in Aethlon Medical Inc (AEMD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
989
|
|
|
907
|
|
|
888
|
|
|
882
|
|
|
808
|
|
|
711
|
|
|
648
|
|
|
648
|
|
|
573
|
| Aethlon Medical Inc. (AEMD) | Ratios |
|---|---|
|
Return on equity(%)
|
-0.44
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Aethlon Medical Inc (AEMD) was $0 Mln.
$-0.13
(
